{"id":"W4327910154","doi":"10.1093/oncolo/oyad022","title":"Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Cancer; Adverse effect; Adenocarcinoma; Phases of clinical research; Chemotherapy; Urology; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001883992,0.0003421077,0.001739139,0.0002859923,0.0003550799,0.00002768122,0.0002956841,0.0001719702,0.0003048028],"category_scores_gemma":[0.0008157265,0.0002182207,0.0001386673,0.0009605803,0.0008834499,0.00008234508,0.0002228355,0.0005732513,0.00006977683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007731692,"about_ca_system_score_gemma":0.0007908538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00221245,"about_ca_topic_score_gemma":0.0006229294,"domain_scores_codex":[0.9972045,0.0003609586,0.0006426754,0.0005259076,0.0004984514,0.0007674837],"domain_scores_gemma":[0.9970275,0.001934823,0.0002040696,0.0005243308,0.00009328564,0.0002160449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7469851,0.002476164,0.2115612,0.0001905857,0.001509112,0.002494239,0.009933747,0.0001089638,0.001076076,0.000241942,0.002126121,0.02129674],"study_design_scores_gemma":[0.7776346,0.009161819,0.1914107,0.0001215034,0.001039746,0.000228269,0.007974469,0.01144666,0.0000577503,0.000252347,0.0003496894,0.0003224573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98658,0.002748348,0.00001291397,0.002953267,0.0002856218,0.004190569,0.00001811827,0.0001504866,0.003060718],"genre_scores_gemma":[0.9892278,0.005882923,0.0001785471,0.0001667378,0.0002102149,0.001134214,0.00002977021,0.00004383938,0.003125934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03064941,"threshold_uncertainty_score":0.8898781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07993181896745435,"score_gpt":0.4131683534045474,"score_spread":0.333236534437093,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}